Bir sonraki

Otomatik oynatma

Dr. Andre Goy on Crizotinib for ALK-positive Pediatric Patients With ALCL

3 Görünümler • 07/30/23
Pay
gömmek
administrator
administrator
Aboneler
0

Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a small phase I trial that used crizotinib (Xalkori) to treat ALK-positive pediatric patients with anaplastic large cell lymphoma (ALCL), neuroblastoma, and inflammatory myofibroblastic tumors (IMTs).

View more at http://www.onclive.com/confere....nce-coverage/asco-20

Daha fazla göster
0 Yorumlar sort Göre sırala
Facebook Yorumları

Bir sonraki

Otomatik oynatma